Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

Go back to Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
(NASDAQ: AXSM) Delayed: 207.82 +1.14 (0.55%)
Previous Close $206.68    52 Week High $15.74 
Open $205.00    52 Week Low $5.37 
Day High $210.86    P/E N/A 
Day Low $202.00    EPS $0.00 
Volume 385,778